

Advent France Biotechnology

Adrien Clavairoly promoted to Senior Associate at Advent France Biotechnology



Adrien Clavairoly has been promoted to Senior Associate at Advent France Biotechnology (AFB). Adrien started at AFB in 2016 as an Analyst and was promoted to Associate in 2020.

As Senior Associate, he will be in charge of sourcing and evaluating innovative projects, conducting due diligence as well as participating in the second round of fund raising for AFB. Adrien participates as board observer of AFB's portfolio companies Augustine Therapeutics, SynHelix and ARTHex Biotech. He also regularly participates in symposiums and juries to help evaluating promising startups.

Adrien Clavairoly, 36, received a Master degree in molecular and cell biology in 2010 and a PhD in neuroscience in 2014, both from the Pierre et Marie Curie University (UPMC), Paris, France.

Adrien's experience includes in-depth scientific knowledge in cellular molecular and developmental biology. He developed alongside scouting, tech transfer, business development and fundraising skills. His main areas of interest are integrative biology and regenerative medicine.

Following his training in molecular pharmacology at Oxford University in 2009, Adrien joined the Pasteur Institute program on neural development and plasticity of the nervous system. He obtained a grant from the French Ministry of Research to undertake a PhD at the Brain and Spine institute (ICM) at the Pitié-Salpêtrière hospital (Paris, France), a unique world-class institute bringing together fundamental and clinical researchers to develop new research models and treatments for brain and spinal cord disorders.

Prior to joining AFB, he participated in the creation of 'La Paillasse', a startup incubator network involved in the DIY-biology movement. He has worked as financial director and community manager of La Paillasse-Paris for two years. His activities helped in raising funds from public and private sources as well as laboratory equipment to open a biotech laboratory dedicated to citizen science.

“As a neurobiologist and founder of a biotech startup incubator, Adrien's knowledge of the French scientific ecosystem is key to identifying early-stage projects, in close collaboration with the technology transfer offices of academic institutions in France.”

Alain Huriez, chairman and co-founder, AFB

In a dynamic life sciences market, investments are booming in Europe and the US. France is fast becoming an extremely attractive market for US investors who have greater investment capabilities but need local partners to develop the most innovative startups.

There's a critical need in France to develop further early-stage funding in similar proportion to that invested in the US, Germany or Switzerland. Public investors such as Bpifrance are moving in this direction, with increased support and financing for the French life sciences and health tech sector.

AFB's role is critical to support the biotech ecosystem, creating value by converting innovations from public research into viable startups, and working together with tech transfer organizations and partners to make the most of every project.